Unknown

Dataset Information

0

Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1-RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1-RUNX1T1.


ABSTRACT: The prognostic significance of KIT mutations and optimal thresholds and time points of measurable residual disease (MRD) monitoring for acute myeloid leukemia (AML) with RUNX1-RUNX1T1 remain controversial in the setting of hematopoietic stem cell transplantation (HSCT). We retrospectively evaluated 166 high-risk patients who underwent allogeneic (Allo-HSCT, n = 112) or autologous HSCT (Auto-HSCT, n = 54). D816V KIT mutation, a subtype of exon 17 mutations, was significantly associated with post-transplant relapse and poor survival, while other types of mutations in exons 17 and 8 were not associated with post-transplant relapse. Pre- and post-transplant RUNX1-RUNX1T1 MRD assessments were useful for predicting post-transplant relapse and poor survival with a higher sensitivity at later time points. Survival analysis for each stratified group by D816V KIT mutation and pre-transplant RUNX1-RUNX1T1 MRD status demonstrated that Auto-HSCT was superior to Allo-HSCT in MRD-negative patients without D816V KIT mutation, while Allo-HSCT was superior to Auto-HSCT in MRD-negative patients with D816V KIT mutation. Very poor outcomes of pre-transplant MRD-positive patients with D816V KIT mutation suggested that this group should be treated in clinical trials. Risk stratification by both D816V KIT mutation and RUNX1-RUNX1T1 MRD status will provide a platform for decision-making or risk-adapted therapeutic approaches.

SUBMITTER: Cho BS 

PROVIDER: S-EPMC7831332 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


The prognostic significance of <i>KIT</i> mutations and optimal thresholds and time points of measurable residual disease (MRD) monitoring for acute myeloid leukemia (AML) with <i>RUNX1-RUNX1T1</i> remain controversial in the setting of hematopoietic stem cell transplantation (HSCT). We retrospectively evaluated 166 high-risk patients who underwent allogeneic (Allo-HSCT, <i>n</i> = 112) or autologous HSCT (Auto-HSCT, <i>n</i> = 54). D816V <i>KIT</i> mutation, a subtype of exon 17 mutations, was  ...[more]

Similar Datasets

| S-EPMC6960455 | biostudies-literature
| S-EPMC8478654 | biostudies-literature
| S-EPMC10248858 | biostudies-literature
| S-EPMC6480444 | biostudies-literature
| S-EPMC4148766 | biostudies-literature
| S-EPMC7116445 | biostudies-literature
| S-EPMC6062501 | biostudies-literature
| S-EPMC4815724 | biostudies-literature
| S-EPMC8140419 | biostudies-literature
| S-EPMC5535027 | biostudies-literature